(Total Views: 696)
Posted On: 07/05/2020 3:59:25 PM
Post# of 149265
Re: Borel Fields #41102
Yes I agree with you on the results by PR. But the publication is so hard to predict. It's nuts I can't believe I'm saying this, but we'll probably have results before Dr. P's paper published.
I'm equally confident in both. Rantes is what is driving the disease so the moa of blocking ccr5 will find consistent efficacy between the two trials.
Knowing that our n value for s/c interim had increased boosts my confidence in the results dramatically. Treatment arm mortality will be near what we've seen in EIND. so expect a mortality rate of ~15 in treatment, maybe better due to randomization, and earlier intervention. Placebo arm might experience higher than I initially expected due to modified exclusion criteria. But still hard to call.
I'm feeling very confident in m2m p value, and confident in s/c p value.
Very confident in m2m p value because of the dozens of papers I've read about the disease course and because I know that MOA will stop the inflammatory process dead in it's tracks.
I'm equally confident in both. Rantes is what is driving the disease so the moa of blocking ccr5 will find consistent efficacy between the two trials.
Knowing that our n value for s/c interim had increased boosts my confidence in the results dramatically. Treatment arm mortality will be near what we've seen in EIND. so expect a mortality rate of ~15 in treatment, maybe better due to randomization, and earlier intervention. Placebo arm might experience higher than I initially expected due to modified exclusion criteria. But still hard to call.
I'm feeling very confident in m2m p value, and confident in s/c p value.
Very confident in m2m p value because of the dozens of papers I've read about the disease course and because I know that MOA will stop the inflammatory process dead in it's tracks.
(5)
(0)Scroll down for more posts ▼
